Detalles de la búsqueda
1.
Novel chimeric antigen receptor-expressing T cells targeting the malignant mesothelioma-specific antigen sialylated HEG1.
Int J Cancer;
154(10): 1828-1841, 2024 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38212893
2.
MMP1, IL-1ß, sTNFR-1, and IL-6 are prognostic factors for patients with unresectable or metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Int J Clin Oncol;
29(6): 832-839, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38580797
3.
A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.
Int J Cancer;
152(12): 2554-2566, 2023 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36727538
4.
Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors.
Cancer Immunol Immunother;
72(8): 2829-2840, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37188764
5.
Exhaustion of CAR T cells: potential causes and solutions.
J Transl Med;
20(1): 239, 2022 05 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-35606821
6.
Evaluation of X-ray and carbon-ion beam irradiation with chemotherapy for the treatment of cervical adenocarcinoma cells in 2D and 3D cultures.
Cancer Cell Int;
22(1): 391, 2022 Dec 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36494817
7.
Clinical significance of peripheral TCR and BCR repertoire diversity in EGFR/ALK wild-type NSCLC treated with anti-PD-1 antibody.
Cancer Immunol Immunother;
70(10): 2881-2892, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-33751180
8.
Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinoma.
Cancer Immunol Immunother;
69(10): 2041-2051, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32424467
9.
Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial.
Cancer Immunol Immunother;
69(5): 847-857, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32025848
10.
Circulating cytokine signatures as a soluble biomarker of immune checkpoint inhibitor therapy in non-small-cell lung cancer.
Genes Immun;
25(1): 89-91, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38097745
11.
Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor.
Int J Cancer;
144(5): 1170-1179, 2019 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30307035
12.
Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial.
Cancer Sci;
110(10): 3049-3060, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31390678
13.
[Translational Research in Immuno-Oncology - Comprehensive Analysis of Phenotypes and Functions of Various Immune Cells Using the Colorectal Cancer Surgical Sample].
Gan To Kagaku Ryoho;
45(9): 1238-1241, 2018 Sep.
Artículo
en Japonés
| MEDLINE | ID: mdl-30237362
14.
Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies.
Cancer Sci;
108(9): 1732-1738, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28622427
15.
A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer.
Cancer Sci;
108(5): 838-845, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28188670
16.
Personalized peptide vaccination as second-line treatment for metastatic upper tract urothelial carcinoma.
Cancer Sci;
108(12): 2430-2437, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28940789
17.
Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11+ or -A33+ allele.
Cancer Sci;
108(4): 598-603, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28178396
18.
Cancer immunotherapy targeting neoantigens derived from tumor-specific gene mutations.
Nihon Rinsho;
75(2): 189-195, 2017 02.
Artículo
en Japonés
| MEDLINE | ID: mdl-30562851
19.
Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients.
Cancer Sci;
107(5): 590-600, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26920496
20.
A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer.
Cancer Immunol Immunother;
65(2): 151-60, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26728480